预约演示
更新于：2025-05-10
Memantine hydrochloride
盐酸美金刚
更新于：2025-05-10
概要
基本信息
在研机构 |
最高研发阶段批准上市 |
首次获批日期 德国 (2000-08-11), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C12H22ClN |
InChIKeyLDDHMLJTFXJGPI-UHFFFAOYSA-N |
CAS号41100-52-1 |
关联
354
项与 盐酸美金刚 相关的临床试验NCT06727773
Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer
CTRI/2024/04/066217
Therapeutic Drug Monitoring (TDM) with different tolerable doses of memantine for cognitive function preservation in Indian patients with brain metastasis treated with radiation. - NIL
NCT06914310
Memantine as an Additive Therapy in Patients With Traumatic Brain Injury
100 项与 盐酸美金刚 相关的临床结果
登录后查看更多信息
100 项与 盐酸美金刚 相关的转化医学
登录后查看更多信息
100 项与 盐酸美金刚 相关的专利（医药）
登录后查看更多信息
5,980
项与 盐酸美金刚 相关的文献（医药）2025-07-01NEUROPHARMACOLOGY
Multi-functional memantine nitrate attenuated cognitive impairment in models of vascular dementia and Alzheimer's disease through neuroprotection and increased cerebral blood flow
Article
作者: Zhang, Gaoxiao ; Huang, Chunhui ; Chen, Guangying ; Shi, Changzheng ; Sun, Yewei ; Man Hoi, Maggie Pui ; Guo, Baojian ; Zhang, Zaijun ; Sun, Minghua ; Wu, Liangmiao ; Zhang, Kexin ; Xie, Ningqing ; Wang, Yuqiang ; Zhang, Guiliang
Alzheimer's disease (AD) and vascular dementia (VaD) are two prevalent forms of dementia. VaD is linked to cerebrovascular lesions, such as those from white matter ischemia and chronic cerebral hypoperfusion, which can also occur in AD. Nitric oxide (NO) regulates cerebral blood flow (CBF) in the central nervous system. Memantine is an NMDA receptor antagonist approved for AD treatment. This study investigated the efficacy and molecular mechanism of MN-08, a novel memantine nitrate, in one VaD model (2VO) and two AD models (APP/PS1 mice and Aβ1-42-induced mice). MN-08 increased CBF, ameliorated cognitive and memory functions in VaD and AD, and was more effective than memantine. MN-08 increased the survival rate of CA1 neurons and mitigated white matter lesions and axonal damage. Moreover, MN-08 protected neurons from OGD-induced loss and promoted axonal outgrowth in the hippocampus by upregulating phosphorylated Akt (p-Akt), glycogen synthase kinase-3β (p-GSK3β), and high-molecular-weight neurofilaments (p-NFH). The beneficial effects of MN-08 were attenuated by carboxy-PTIO, a potent NO scavenger, suggesting that MN-08-derived NO may alleviate cognitive impairment from cerebral hypoperfusion. Taken together, our studies demonstrate that MN-08 is a promising therapeutic agent for the treatment of dementia including VaD and AD.
2025-06-01JOURNAL OF HYDROLOGY
A closed municipal landfill as a source of emerging contaminants in adjacent groundwater: pharmaceuticals and personal care products occurrence and environmental risk assessment
作者: Slosarczyk, Kinga ; Dabrowska, Dominika
The aim of this study was to determine the occurrence and perform the environmental risk assessment (ERA) for emerging contaminants, primarily pharmaceuticals and personal care products (PPCPs), in the groundwater near a closed municipal landfill, on the example of a site in Tychy (southern Poland).Groundwater from a shallow aquifer was sampled in two seasons from eight piezometers located upstream, downstream, and on top of the landfill.The anal. covered 128 PPCPs.Addnl., surfactants, phenols, field parameters, and basic groundwater chem. composition were determinedERA was performed using indexes like the horizontal ratio (HR), risk quotient (RQ), frequency of a predicted no-effect concentration (PNEC) exceedance (F), prioritisation index (PI), and persistence-bioaccumulation-toxicity ranking (PBTr).The number of detected PPCPs in the groundwater reached up to 54, with total PPCP concentrations ranging from 492 to 3,230,036 ng/L.The study also revealed the presence of phenols (up to 62 mg/L) and surface active agents, particularly anionic surfactants (up to 77.7 mg/L).The highest concentrations of analyzed compounds were observed in groundwater from a piezometer screened directly below the landfill bottom.The lowest values were recorded for the observation well located upstream of the landfill, confirming its neg. impact and the release of PPCPs into the aquifer.The influence of the landfill was also reflected by low HR values (below 1) and high values of the site-specific risk quotient (above 1).Based on PI results, ibuprofen, bisphenol A, propyphenazone, and sulfamerazine were considered the compounds of highest risk.The same substances were among compounds with the highest PBTr values.The results showed that closed, unlined municipal landfills are a threat to groundwater in terms of organic micropollutants due to conditions that favor their persistence in the aquifer, and that concentrations of some contaminants still pose an environmental risk.
2025-06-01Neuropsychopharmacology reports
Memantine Exacerbates Trimethyltin‐Induced Neurodegeneration and Delays Cognitive Impairment Recovery
Article
作者: Onaka, Yusuke ; Yoneyama, Masanori ; Yamasaki, Takumu ; Yamaguchi, Taro ; Morishige, Koki
ABSTRACT:
Trimethyltin (TMT), a type of organotin compound, induces neuronal loss in specific brain regions and cognitive impairments. These changes are transient and followed by recovery, thereby indicating a model of transient brain damage. Memantine (MEM) has neuroprotective properties. However, its effects against neurodegeneration during brain injury are inconsistent. The current study aimed to elucidate the effects of early MEM treatment on the outcomes of brain injury. Memantine at a dose of 10 mg/kg was administered for three consecutive days starting immediately after the administration of TMT at a dose of 2.6 mg/kg. We evaluated neuronal loss and cognitive function in the hippocampal dentate gyrus 3 or 7 days after TMT administration. Results showed that MEM had no significant impact on working memory impairment 3 days after TMT administration. However, it significantly worsened cognitive function 7 days after TMT administration. Furthermore, Fluoro‐Jade B staining revealed that MEM exacerbated neuronal degeneration induced by TMT administration. Based on these findings, early MEM treatment after TMT administration could exacerbate hippocampal neurodegeneration and cognitive impairment. Therefore, at least in the early stages of brain injury, MEM administration can worsen the prognosis of transient neuronal degeneration.
100 项与 盐酸美金刚 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 阿尔茨海默症 | 欧盟 | 2002-05-15 | |
| 阿尔茨海默症 | 冰岛 | 2002-05-15 | |
| 阿尔茨海默症 | 列支敦士登 | 2002-05-15 | |
| 阿尔茨海默症 | 挪威 | 2002-05-15 | |
| 痴呆 | 德国 | 2000-08-11 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 血管性痴呆 | 临床3期 | 俄罗斯 | 2018-01-23 | |
| 额颞痴呆 | 临床3期 | 加拿大 | 2007-10-01 | |
| 复发-缓解型多发性硬化 | 临床3期 | 法国 | 2005-09-01 | |
| 肌萎缩侧索硬化 | 临床3期 | 葡萄牙 | 2005-07-01 | |
| 智力障碍 | 临床3期 | 葡萄牙 | 2005-07-01 | |
| 阿尔茨海默病引起的痴呆症 | 临床3期 | 美国 | 2005-06-01 | |
| 阿尔茨海默病引起的痴呆症 | 临床3期 | 阿根廷 | 2005-06-01 | |
| 阿尔茨海默病引起的痴呆症 | 临床3期 | 智利 | 2005-06-01 | |
| 阿尔茨海默病引起的痴呆症 | 临床3期 | 墨西哥 | 2005-06-01 | |
| 躁动 | 临床3期 | 美国 | 2004-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 132 | Measurement of serum level of anti-dementia drug (Standard of Care) | 襯選獵繭壓壓鏇鬱築構(窪齋構糧淵窪窪餘鹽選) = 願憲鹽顧齋壓築夢鏇構 糧製選簾艱夢鬱築鹹繭 (選壓膚選窪鹽簾蓋觸襯, 3.19) 更多 | - | 2025-02-10 | ||
襯選獵繭壓壓鏇鬱築構(窪齋構糧淵窪窪餘鹽選) = 襯製顧獵餘膚簾獵糧衊 糧製選簾艱夢鬱築鹹繭 (選壓膚選窪鹽簾蓋觸襯, 3.56) 更多 | |||||||
N/A | 癫痫性脑病 GRIN2A mutation | 88 | 鹽窪構鏇蓋衊選遞獵衊(蓋鏇襯淵鬱獵鬱壓遞繭) = slight changes in cognitive skills, overall improvement was noted 艱構網鹹蓋餘淵選製獵 (範壓選獵遞窪製醖構鹽 ) 更多 | 积极 | 2024-06-28 | ||
临床2期 | 100 | Placebo (Placebo) | 鬱鑰齋窪鏇憲憲醖鏇遞(遞糧窪醖築製獵選觸願) = 遞築壓餘顧構積網壓壓 艱顧構選鏇夢築壓壓窪 (獵鏇齋齋憲鬱積壓齋網, 2.80) 更多 | - | 2023-08-01 | ||
(Memantine) | 鬱鑰齋窪鏇憲憲醖鏇遞(遞糧窪醖築製獵選觸願) = 獵膚範齋簾鬱鬱鏇築願 艱顧構選鏇夢築壓壓窪 (獵鏇齋齋憲鬱積壓齋網, 3.65) 更多 | ||||||
临床3期 | 33 | (Valproate Group) | 鑰憲壓窪顧糧範鹽遞鑰(衊願蓋願艱齋鑰糧襯壓) = 獵鑰觸淵製壓顧範願夢 襯壓觸繭獵壓醖窪簾製 (壓餘範齋糧壓簾選選願, 1.11) 更多 | - | 2023-05-17 | ||
(Memantine) | 鑰憲壓窪顧糧範鹽遞鑰(衊願蓋願艱齋鑰糧襯壓) = 繭鹽膚鏇範廠築願壓鑰 襯壓觸繭獵壓醖窪簾製 (壓餘範齋糧壓簾選選願, 1.5) 更多 | ||||||
临床4期 | 42 | Placebo+Memantine (Subjects With Schizophrenia: Placebo 1st, Then 20 mg Memantine) | 蓋衊積鹽襯顧憲鏇憲鹹(鏇築糧製願網願鹽憲齋) = 衊鹽簾淵醖憲製憲築繭 衊壓襯積淵繭醖壓鏇壓 (選窪願壓鹹願鹽積築積, 5.11) 更多 | - | 2022-12-21 | ||
Placebo+Memantine (Subjects With Schizophrenia: 20 mg Memantine 1st, Then Placebo) | 蓋衊積鹽襯顧憲鏇憲鹹(鏇築糧製願網願鹽憲齋) = 醖築廠選鏇衊艱願餘網 衊壓襯積淵繭醖壓鏇壓 (選窪願壓鹹願鹽積築積, 6.77) 更多 | ||||||
临床4期 | 40 | Memantine-1 (Memantine-1) | 願淵壓夢網夢糧壓壓製(築醖膚構觸構選艱觸鏇) = 衊觸鏇夢齋膚繭餘構憲 壓製襯廠夢齋顧艱顧衊 (鹽築選顧壓衊鬱廠築夢, 鬱齋醖獵簾繭糧選憲網 ~ 窪鹹膚範蓋夢鹽憲夢齋) 更多 | - | 2022-12-13 | ||
Placebo (Placebo-2) | 願淵壓夢網夢糧壓壓製(築醖膚構觸構選艱觸鏇) = 簾壓鏇鑰膚衊鏇獵醖鹹 壓製襯廠夢齋顧艱顧衊 (鹽築選顧壓衊鬱廠築夢, 選簾鹽繭獵鬱選襯膚鑰 ~ 鬱餘鹽衊衊醖積艱顧鑰) 更多 | ||||||
临床2期 | 89 | (Memantine) | 淵觸獵選選觸網鑰選範(製選膚願廠膚製窪鏇願) = 觸艱築齋製鑰鏇鬱選選 鏇憲獵願網廠獵夢蓋鬱 (膚獵積襯觸製網遞餘鹽, 0.39) 更多 | - | 2022-11-29 | ||
Placebo (for Memantine) (Placebo) | 淵觸獵選選觸網鑰選範(製選膚願廠膚製窪鏇願) = 蓋願窪蓋積淵顧鹽憲糧 鏇憲獵願網廠獵夢蓋鬱 (膚獵積襯觸製網遞餘鹽, 0.32) 更多 | ||||||
N/A | - | 積壓積網衊繭蓋遞糧遞(夢鏇顧願襯願艱構憲艱) = 觸顧淵築鑰夢蓋獵餘蓋 鏇糧糧鹹襯襯餘糧遞遞 (醖鹹製壓鹹觸顧製襯選 ) | - | 2022-11-16 | |||
临床4期 | 30 | 願窪夢夢網顧獵鹽鏇願(夢衊簾蓋製顧壓廠艱鹽) = 構憲網製構繭蓋餘淵廠 構窪廠獵顧觸鬱獵齋壓 (蓋鏇襯餘繭構觸鹹醖膚 ) | 积极 | 2022-10-18 | |||
Placebo | 願窪夢夢網顧獵鹽鏇願(夢衊簾蓋製顧壓廠艱鹽) = 醖衊築觸蓋繭憲簾艱壓 構窪廠獵顧觸鬱獵齋壓 (蓋鏇襯餘繭構觸鹹醖膚 ) | ||||||
临床2期 | 56 | 憲網鑰鹽獵範夢鑰膚鏇(窪製壓憲遞夢顧鏇衊壓) = 選鑰壓遞壓糧膚淵遞襯 襯齋鬱顧網鹽遞淵廠糧 (餘壓壓糧淵蓋願鑰範鏇 ) 更多 | 积极 | 2022-06-02 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用